Neurochem Inc.
Shares declined $2.40 to $3.16 after the drug developer said a study of its Alzheimer's disease drug candidate Alzhemed did not show a statistically significant benefit, compared with a placebo.
Stock of interest
The Baltimore Sun
Copyright
© 2021, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad